Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viatris

Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

NEW YORK , March 11, 2024 /PRNewswire/ -- IN THE COURT OF COMMON PLEAS OF ALLEGHENY COUNTY, PENNSYLVANIA RAJESH PATEL, Individually and on Behalf of All Others Similarly Situated,                                                   Plaintiff, v. VIATRIS, INC.

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

A former information technology executive at Mylan pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 million of illegal profit, authorities said.

Former Mylan executive pleads guilty to insider trading

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Mylan (VTRS) Stock Undervalued Right Now?

Pfizer

The two pharma stocks offer investors the upside of a coronavirus vaccine with the peace of mind of century-old businesses.

2 Best Pharma Stocks to Buy in November

Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.

Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss

Mylan (MYL) delivered earnings and revenue surprises of 14.78% and -0.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Q3 Earnings Surpass Estimates

There really isn't a downside to this deal.

3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.

Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Mylan (MYL) Might Surprise This Earnings Season

HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski, CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership. He will be serving in that same...

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

The Federal Trade Commission has signed off on the deal.

Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit

HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC's review of the proposed combination of Mylan and Pfizer's Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris Trust transaction, pursuant

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Mylan (MYL) Beat Estimates Again in Its Next Earnings Report?

In this article you are going to find out whether hedge funds think Mylan N.V. (NASDAQ:MYL) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It's not surprising given that hedge funds have access to better information and more resources to predict the winners in the stock market.

Were Hedge Funds Right About Souring On Mylan N.V. (MYL)?

Going by the historical performance, we believe that the stock price of Mylan, a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current levels. MYL stock trades at $15 currently and it is down 35% from the pre-Covid high of $23 seen in February.

Mylan Stock Has Over 45% Upside

CVS Health

Hewlett Packard

Intel

Kroger

Lennar

AT&T

Molson Coors Brewing

Tapestry

Tyson Foods

Two traders sift through a group of stocks "on sale" to find bargain buys in the market.

These stocks trading at discounts to their valuations may be worth buying, traders say

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

HERTFORDSHIRE, England and PITTSBURGH, Sept. 15, 2020 /PRNewswire/ -- Mylan N.V.

Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL

Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.

Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe

HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.

Mylan to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Mylan to Present at the BofA Securities Virtual Global Healthcare Conference

Mylan N.V. MYL, +2.26% said Tuesday it will pay EUR641.9 million ($756.8 million) for Aspen Pharmacare Holdings Ltd.

Mylan to pay equivlant of $757 million to buy Aspen's  Europe thrombosis business

HERTFORDSHIRE, England, and PITTSBURGH, Sept. 8, 2020 /PRNewswire/ -- Mylan N.V.

Mylan to Acquire Aspen's Thrombosis Business in Europe

Mylan (MYL) reported earnings 30 days ago. What's next for the stock?

News for Mylan Stock (MYL)